drugset / Trial / NCT06246162
Mitoxantrone Hydrochloride Liposome Combination Regimen in the Treatment of High-risk/Extramedullary Multiple Myeloma
NaSingle-groupOpen-labelTreatment
Summary
To evaluate the efficacy and safety of mitoxantrone Hydrochloride Hydrochloride Liposome combination regimen in the treatment of high-risk/extramedullary multiple myeloma
Timeline
- Start
- 2023-11-13
- Primary completion
- 2025-11-30
- Completion
- 2026-11-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bortezomib | Small molecule | 1.3 mg/m2 | Subcutaneous |
| Subject | Dexamethasone | Small molecule | 20 mg | Oral |
| Subject | Mitoxantrone | Small molecule | 10 mg | Intravenous |
| Subject | Pomalidomide | Other / unclassified | 4 mg | Oral |